Scientists have disproved a decades-old orthodoxy: Cerebrospinal fluid does not leave the cranial cavity via blood vessels, but instead through the lymphatic system.
This finding has far-reaching implications in new treatments for dementia.
The brain sits fully immersed in an aqueous liquid called cerebrospinal fluid. Every day, the human body produces about half a liter of new cerebrospinal fluid in the cerebral ventricles; this liquid originates from the blood. This same quantity then has to exit the cranial cavity again every day.
Researchers in the group led by Michael Detmar, professor of pharmacogenomics at ETH Zurich, have now published a study showing that in mice, the cerebrospinal fluid exits the cranial cavity through the lymph vessels.
The work, published in Nature Communications, identifies another central role of the lymphatic system.
Past research has inadequately explained how cerebrospinal fluid exits the cranial cavity. Scientists knew that two paths were available—blood vessels (veins) and lymphatic vessels—but for a long time, and due to insufficient research tools, they had assumed that drainage through the veins was by far the predominant pathway.
The researchers, led by Steven Proulx, senior scientist in Detmar’s group, have now been able to refute this assumption. They injected tiny fluorescent dye molecules into the ventricles (cavities) of the brain in mice and observed how these molecules exited the cranial cavity.
They used a sensitive non-invasive imaging technique to examine the blood vessels in the periphery of the animals’ bodies, as well as the lymphatic and blood vessels directly draining the skull.
It turned out that the dye molecules appeared after just a few minutes in the lymphatic vessels and lymph nodes outside the brain. The researchers were unable to find any molecules in blood vessels so quickly after the injection.
They were also able to determine the exact path of the dye molecules and thus the cerebrospinal fluid: It leaves the skull along cranial nerve sheaths—in particular around the olfactory and optic nerves. “Once in tissue outside the brain, it is removed by the lymphatic vessels,” explains Qiaoli Ma, a doctoral student in Detmar’s group and lead author of the study.
The scientists are not entirely able to rule out whether a small portion of the cerebrospinal fluid also leaves the brain through the veins. However, based on their research findings, they are convinced that the lion’s share travels through the lymphatic system, and that the anatomy textbooks will require editing.
Flushing the brain
Scientists assume that the circulation of cerebrospinal fluid has a purifying function. “The immune system eliminates toxins elsewhere in the body, but the brain is considered to be largely disconnected from this system. Only a few immune cells have access under normal conditions,” explains Proulx.
“The cerebrospinal fluid steps into the breach here. By constantly circulating, it flushes the brain and removes unwanted substances.”
This flushing function could offer a starting point for treatment of neurodegenerative diseases such as Alzheimer’s. Misfolded proteins that accumulate in the brain cause Alzheimer’s. Proulx and his colleagues speculate that these misfolded proteins could be eliminated by, for example, drugs that induce lymphatic flow.
Similarly, studies could take place to examine whether it is possible to manage inflammatory diseases of the central nervous system, such as multiple sclerosis, through influence of the lymphatic flow.
Slower flow in old age
The scientists also showed that much less cerebrospinal fluid flows out of the brain in older mice than in younger ones, presumably because less fluid is produced in old age. Since Alzheimer’s and other forms of dementia occur in old age, the researchers think it will be interesting to examine whether stimulation of the flow of cerebrospinal fluid could slow down the progression of dementia. This is the question the scientists would like to explore next in a mouse model.
Detmar’s group has already shown that other diseases outside the brain can be treated by stimulation of the lymphatic flow. In the case of rheumatoid arthritis and psoriasis, the researchers succeeded in relieving symptoms through stimulation of the lymphatic flow.
The researchers say that studies on cerebrospinal outflow in humans may be conceivable in the future. The fluorescent marker molecule does not trigger an immune reaction and is efficiently eliminated by the body. Before the molecule can be used in humans, the scientists must first apply for the necessary approval.
“Research on the lymphatic system did not receive the attention it deserved until recently. Some in the scientific world have even ignored the lymphatic system altogether,” says Proulx.
Source: ETH Zurich